findmyKOL
Clinical trialNCT07594626Not, yet, recruitingPhase 1/PHASE2Interventional

BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion

SponsorNorthwestern UniversityEnrollment72Metastatic Biliary Tract CarcinomaMetastatic Colon CarcinomaMetastatic Esophageal CarcinomaMetastatic Malignant Digestive System NeoplasmMetastatic Malignant Solid NeoplasmMetastatic Pancreatic Carcinoma+2 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Northwestern University

    Chicago, Illinois, United States

    Devalingam Mahalingam, MD, PhD

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
9 Dec 2027
Primary completion
9 Dec 2030
Completion
9 Dec 2030
Last update posted
19 May 2026
Registered enrollment
72
Registry id
NCT07594626
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.